You are here: Industry Insights > REVLIMID

News List

BMS 2Q Revenues up 16% contractpharma
August 02, 2021
Top sellers Revlimid, Eliquis and Opdivo drive growth while established brands were down 64%.
Sun Pharma announces settlement of patent litigation for generic Revlimid in the US expresspharma
June 23, 2021
Sun Pharma, along with one of its wholly-owned subsidiaries today announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding ...
NICE recommends Revlimid for newly diagnosed multiple myeloma patients pharmatimes
January 27, 2021
Bristol Myers Squibb’s (BMS) Revlimid (lenalidomide) has received a recommendation from the UK’s National Institute of Health and Care Excellence (NICE) for newly diagnosed multiple myeloma patients.
Cipla settles patent litigation of Revlimid (lenalidomide) capsules with Celgene expresspharma
December 14, 2020
Celgene has agreed to provide Cipla with a license to Celgene’s patents required to manufacture and sell certain volume-limited amounts of generic lenalidomide in the US beginning on a confidential date that is some time after March 2022.
NICE turns down Celgene's Revlimid as multiple myeloma maintenance treatment pharmatimes
September 23, 2020
The National Institute for Heath and Care Excellence (NICE) has turned down NHS funding of Celgene's Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Empliciti, Revlimid combo falls short in multiple myeloma pharmatimes
March 12, 2020
Bristol-Myers Squibb has revealed that Empliciti (elotuzumab), when added to BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone, has not proved successful in extending the time patients with newly-diagnosed myeloma who were ineligible for ...
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma drugs
May 29, 2019
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma.
NICE recommends Revlimid as multiple myeloma alternative pharmatimes
May 20, 2019
The National Institute of Health and Care Excellence (NICE) has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight blood cancer.
Celgene dodges Alvogen bid to overturn Revlimid patent PharmaSources/biopharmadive
March 18, 2019
Revlimid (lenalidomide) is a crucial drug for Celgene and its nearly $10 billion in annual revenue is a key part of Bristol-Myers' deal to buy the storied biotech.
Celgene gets fast FDA review of Revlimid combo in lymphoma pharmaphorum
February 28, 2019
Celgene is closing in on yet another new indication for its blood cancer blockbuster Revlimid, with the FDA starting a priority review of the drug in combination with Roche’s Rituxan.

Previous page 1 2 Next page